These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19571438)

  • 1. Different enzyme kinetics of midazolam in recombinant CYP3A4 microsomes from human and insect sources.
    Christensen H; Mathiesen L; Postvoll LW; Winther B; Molden E
    Drug Metab Pharmacokinet; 2009; 24(3):261-8. PubMed ID: 19571438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells.
    Andrews J; Abd-Ellah MF; Randolph NL; Kenworthy KE; Carlile DJ; Friedberg T; Houston JB
    Xenobiotica; 2002 Nov; 32(11):937-47. PubMed ID: 12487724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
    Gorski JC; Hall SD; Jones DR; VandenBranden M; Wrighton SA
    Biochem Pharmacol; 1994 Apr; 47(9):1643-53. PubMed ID: 8185679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures.
    Mooiman KD; Maas-Bakker RF; Rosing H; Beijnen JH; Schellens JH; Meijerman I
    Biomed Chromatogr; 2013 Sep; 27(9):1107-16. PubMed ID: 23674377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine.
    Maekawa K; Yoshimura T; Saito Y; Fujimura Y; Aohara F; Emoto C; Iwasaki K; Hanioka N; Narimatsu S; Niwa T; Sawada J
    Xenobiotica; 2009 Feb; 39(2):140-7. PubMed ID: 19255940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs.
    Nakajima M; Nakamura S; Tokudome S; Shimada N; Yamazaki H; Yokoi T
    Drug Metab Dispos; 1999 Dec; 27(12):1381-91. PubMed ID: 10570018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro.
    Oda Y; Mizutani K; Hase I; Nakamoto T; Hamaoka N; Asada A
    Br J Anaesth; 1999 Jun; 82(6):900-3. PubMed ID: 10562786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity.
    Christensen H; Hestad AL; Molden E; Mathiesen L
    Xenobiotica; 2011 Jan; 41(1):1-5. PubMed ID: 20954901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4.
    Lee CA; Kadwell SH; Kost TA; Serabjit-Singh CJ
    Arch Biochem Biophys; 1995 May; 319(1):157-67. PubMed ID: 7771780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
    Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
    Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone.
    Miyazaki M; Nakamura K; Fujita Y; Guengerich FP; Horiuchi R; Yamamoto K
    Drug Metab Dispos; 2008 Nov; 36(11):2287-91. PubMed ID: 18669585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4.
    Gallagher EP; Kunze KL; Stapleton PL; Eaton DL
    Toxicol Appl Pharmacol; 1996 Dec; 141(2):595-606. PubMed ID: 8975785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities.
    Nakajima M; Tane K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
    J Pharm Sci; 2002 Apr; 91(4):952-63. PubMed ID: 11948533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study.
    Hamaoka N; Oda Y; Hase I; Mizutani K; Nakamoto T; Ishizaki T; Asada A
    Clin Pharmacol Ther; 1999 Aug; 66(2):110-7. PubMed ID: 10460064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies.
    Hamaoka N; Oda Y; Hase I; Asada A
    Br J Anaesth; 2001 Apr; 86(4):540-4. PubMed ID: 11573629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
    Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
    Huang W; Lin YS; McConn DJ; Calamia JC; Totah RA; Isoherranen N; Glodowski M; Thummel KE
    Drug Metab Dispos; 2004 Dec; 32(12):1434-45. PubMed ID: 15383492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UPLC-MS/MS analysis of the Michaelis-Menten kinetics of CYP3A-mediated midazolam 1'- and 4-hydroxylation in rat brain microsomes.
    Venkatapura Chandrashekar D; DuBois B; Mehvar R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1180():122892. PubMed ID: 34388602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.
    Gibbs MA; Thummel KE; Shen DD; Kunze KL
    Drug Metab Dispos; 1999 Feb; 27(2):180-7. PubMed ID: 9929500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
    Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
    Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.